What Mazdutide is
Mazdutide is a GLP-1 / glucagon dual agonist developed by Innovent and Eli Lilly, furthest along in Chinese Phase 3 trials for obesity and diabetes. It is not FDA approved. Published pharmacokinetic data is thinner than for the other incretins here, so treat the curve as approximate.
What we do not know
- Nearly all published trials enrolled Chinese populations. Whether the dose response transfers to other populations is untested.
- Not approved outside its development region, and Western regulatory review has not happened.
- Long-term outcome data does not exist.
Reconstitution math
Concentration is everything: the same 10 mg vial gives a different draw for every amount of bacteriostatic water you add. The table uses the common 2 mL setup for each vial size, which puts every unit on a U-100 insulin syringe at 50 mcg for the default vial. Dashes mark draws too small to measure or larger than the syringe.
| Vial | BAC water | Concentration | 2 mg | 4 mg | 6 mg |
|---|---|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL | 80 u | - | - |
| 10 mg | 2 mL | 5 mg/mL | 40 u | 80 u | - |
Dosing and protocol
Phase 1b weekly escalation, 6 mg cohort: 2 to 4 to 6 mg.
The Phase 1b escalation stepped 2, then 4, then 6 mg weekly in four-week holds. Higher-dose cohorts (9 and 10 mg) have been studied, but 6 mg is the best-documented maintenance point.
Pharmacokinetics
Mazdutide has published human pharmacokinetics: published terminal half-life spans a wide range; the curve uses a representative 6.5 days. The curves below are normalized one-compartment models built from the cited half-life, the same math the Planner uses. They show shape and timing, not absolute blood levels.
How it is thought to work
A GLP-1 and glucagon dual agonist derived from oxyntomodulin, developed primarily in China. Mechanistically it sits alongside survodutide.
What the evidence supports
This table grades how well each outcome has been studied in humans, not how well Mazdutide works. A strong grade means the question was asked properly, and the answer may still have been negative. Nothing here is inherited from a drug class, a close analog, or the parent molecule of a fragment.
| Outcome | Strongest published evidence |
|---|---|
| Glycemic control | Human RCT |
| Weight loss | Human RCT |
| Cardiovascular outcomes | No data |
Storage and handling
Lyophilized vials keep best cold, dark, and dry; refrigeration is the community default and freezing lyophilized powder is common for long holds. After reconstitution, refrigerate at 2 to 8 C, do not freeze the solution, and date the vial. Bacteriostatic water's preservative keeps multi-dose use practical for about 28 days by USP convention, though our 120-day stability study found the preservative itself outlasts that window.
Got a certificate of analysis with your vial? Run it through our COA Reader: it reads the report in plain English, checks purity and mass against the label claim, and links the testing lab’s own verification page. Our guide to reading a COA explains what the numbers do and do not tell you.
Sources
- Mazdutide (IBI362) 9 mg / 10 mg Phase 1b, eClinicalMedicine 2022PMC9561728
- IBI362 Phase 1b multiple ascending dose studyPMC8374649